Results 91 to 100 of about 22,081 (298)
Primary testicular non-Hodgkin's lymphoma: a review article
Primary testicular non-Hodgkin's lymphoma was first described as a clinical entity in 1866. It is a rare disease and accounts for 1% of all non-Hodgkin's lymphoma, 2% of all extranodal lymphomas and 5% of all testicular neoplasms.
Komal Bhatia+4 more
doaj +1 more source
Heart Failure Resulting from Chemotherapy for Testicular Neoplasm: A Follow-Up on a Patient Reported 20 Years Earlier [PDF]
David Dmitry Boltan+2 more
openalex +1 more source
Abstract Background Low‐trauma fractures of the hip signify osteoporosis and increase the risk of a second fracture. However, screening for secondary osteoporosis and initiating osteoporosis treatment can be challenging in a geriatric population.
Jeppe B. Rosenbæk+5 more
wiley +1 more source
This repeated cross‐sectional study examined trends in CT use, costs and associated radiation dosages between high‐level clinical groups. CT use increased for most patient groups though the degree of increase varied between groups, while trends in costs and radiation dosages varied substantially between clinical groups. This work highlights areas which
Sviatlana Kamarova+12 more
wiley +1 more source
Genital Crohn's disease in pediatrics and genetic associations
Abstract Genital edema is a rare presentation of Crohn's disease (CD), also known as metastatic CD (MCD). This may precede, co‐occur with, or follow gastrointestinal symptoms and present a diagnostic challenge. We aimed to characterize the features, clinical courses, pathogenesis, and outcomes of patients with MCD to increase understanding and promote ...
Erica Chang+5 more
wiley +1 more source
Synchronous Leydig Cell Tumor and Seminoma in the Ipsilateral Testis
Leydig cell tumor is a rare sex cord tumor that accounts for 1–3% of all testicular neoplasms. Seminomas are more common and occur in 30–40% of testicular tumors.
Ifeyinwa E. Obiorah+2 more
doaj +1 more source
The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R‐CHOP) is the first‐line treatment for non‐Hodgkin lymphoma (NHL). Nine articles involving 331 patients were included in the meta‐analysis, the pooled proportion of reproductive adverse events was 22.3% (95% CI 11.4%–33.2%; p < 0.001). The findings
Rong Han+6 more
wiley +1 more source
Primary Cancer Sites and Clinical Features of Choroidal Metastasis in Mexican Patients
Guillermo Salcedo-Villanueva,1 Abraham Alejandro Medina-Andrade,1 Daniel Moreno-Paramo,2 Maria Fernanda Golzarri,1 Edel Moreno-Paramo,1 Grecia Yael Ortiz-Ramirez,1 Ursula Martinez-Aguilar,3 Ulises De Dios-Cuadras,3 Martin Jimenez-Rodriguez,4 Itzel ...
Salcedo-Villanueva G+15 more
doaj
Filarial Orchitis due to Wuchereria bancrofti Masquerading as Testicular Neoplasm [PDF]
Shashikant Patne+2 more
openalex +1 more source